Clinical Evaluation of WaveLight Plus LASIK

NCT07127757 | Recruiting FDA Device

• 1 other identifier: KS-25-01
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a single-site, single-arm, prospective, observational study of subject satisfaction, quality of vision, and quality of life after bilateral LASIK surgery. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the adapted PROWL and Low Luminance Questionnaire (LLQ-32) Questionnaire.

Conditions

Myopia; Astigmatism

Outcome Measures

Primary Outcomes (3)

• % of eyes with UDVA of 20/10, 20/12.5, 20/16 and 20/20 in photopic conditions at 3 months (monocular and binocular)

  3 months postoperatively

• % of eyes with UDVA of 20/10, 20/12.5, 20/16 and 20/20 in mesopic conditions at 3 months (monocular and binocular)

  3 months postoperatively

• % of eyes with CDVA of 20/10, 20/12.5, 20/16 and 20/20 in photopic conditions at 3 months (monocular and binocular)

  3 months postoperatively

Secondary Outcomes (5)

• % of eyes that achieve UDVA equal to or better than preoperative CDVA

  3 months postoperatively

• % of eyes with lines gained/lost lines (post-up UDVA VS pre-op CDVA)

  3 months postoperatively

• % of eyes with absolute MRSE within +/- 0.25, 0.50, 0.75, and 1.00D at 3 months

  3 months postoperatively

• % of eyes that achieved manifest refraction cylinder within +/- 0.25, 0.50, 0.75, and 1.00D at 3 months

  3 months postoperatively

• Patient-Reported Outcomes with the modified PROWL Questionnaire and Low Luminance Questionnaire (LLQ-32) at 3 months

  3 months postoperatively

Other Outcomes (4)

• % of eyes with 10% contrast UDVA (mesopic, binocular) of 20/10, 20/12.5, 20/16, 20/20 and 20/25 at 3 months

  3 months postoperatively

• % of eyes with 10% contrast CDVA (mesopic, binocular) of 20/10, 20/12.5, 20/16, 20/20 and 20/25 at baseline and 3 months

  3 months postoperatively

• % of eyes with UDVA of 20/8 in photopic conditions at 3 months (monocular and binocular)

  3 months postoperatively

Study Arms (1)

Wavelight Plus LASIK

Device: Wavelight Plus LASIK

Interventions

Wavelight Plus LASIK DEVICE

Wavelight plus LASIK is an advanced laser eye surgery technology designed to enhance visual outcomes through personalized treatment plans. This system integrates comprehensive diagnostics, including biometry, tomography, and wavefront measurements, to create a tailored ablation profile for each patient.

Wavelight Plus LASIK

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Eligible test subjects will be 18+ years of age and who are candidates for Wavelight Plus LASIK to correct myopia or myopic astigmatism. Patients who are eligible for LASIK surgery with the Wavelight Plus device may undergo the procedure even if they choose not to participate in the research study. The decision to perform surgery with the device will be made based on clinical indications, irrespective of participation in the study.

You may qualify if:

• Subject must be able to understand and sign an IRB approved Informed consent form
• Willing and able to attend all scheduled study visits as required per protocol
• Minimum of 18 years of age
• Myopia up to -8.00 D, astigmatism up to -3.00 D, with SE more than -1.00D and up to -9.00D, based on Sightmap measured refraction
• Best corrected photopic distance visual acuity of 20/20-2 or better (≤ 0.04 logMAR)
• Mesopic pupil size ≥ 4.5mm
• Less than 0.75 D manifest refraction spherical equivalent difference between Sightmap refraction and subjective manifest refraction
• Stable refraction (within ± 0.50 D) as determined by manifest refraction spherical equivalent for a minimum of 12 months prior to surgery, verified by consecutive subjective refractions or medical records or prescription history
• If currently wearing contact lenses:
• Soft CTL wearers discontinue for minimum 3 days prior to first refraction
• RGP or toric soft CTL wearers discontinue for ≥2 weeks prior to first refraction

You may not qualify if:

• Subjects who are pregnant or nursing
• Acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study
• Patients with flap complications
• Systemic medications that may confound the outcome of the study or increase the risk to the subject.
• Ocular condition (other than high myopia) that may predispose the subject to future complications, such as ectasia
• History or evidence of active or inactive corneal disease (e.g., herpes simplex keratitis, herpes zoster keratitis, recurrent corneal erosion syndrome, corneal dystrophy)
• Evidence of retinal vascular disease
• Keratoconus or Keratoconus suspect
• Glaucoma or glaucoma suspect by exam findings and/or family history
• Previous intraocular or corneal surgery
• Predicted residual stromal bed thickness \< 250 μm
• Intended to have monovision treatment
• Participation in other current clinical trials

Sponsors & Collaborators

• Laser Defined Vision: lead
• Sengi: collaborator

Study Sites (1)

Laser Defined Vision

Greensboro, North Carolina, 27401, United States

RECRUITING

MeSH Terms

Conditions

Myopia; Astigmatism

Interventions

Keratomileusis, Laser In Situ

Condition Hierarchy (Ancestors)

Refractive Errors; Eye Diseases

Intervention Hierarchy (Ancestors)

Corneal Surgery, Laser; Laser Therapy; Therapeutics; Ablation Techniques; Surgical Procedures, Operative; Keratectomy; Refractive Surgical Procedures; Ophthalmologic Surgical Procedures

Study Officials

• Karl Stonecipher, MD

  Laser Defined Vision

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Carrie Williams

CONTACT

336-288-8823; ldv2020@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 11, 2025
• First Posted: August 17, 2025
• Study Start: August 28, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: October 2, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)